IP Library Granted Patent US 7,442,551
Granted Patent B2
US 7,442,551 · App. 11/428,118 · Granted Oct 28, 2008

Lentiviral packaging constructs

Assignee: Novartis AG
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,442,551
App. No.
11/428,118
Granted
Oct 28, 2008
Kind
B2
Abstract

The present invention provides novel lentiviral packaging constructs that are useful for the establishment of stable packaging cell lines and producer cell lines. In particular, the present invention provides novel packaging cell lines that are capable of constitutively expressing high levels of lentiviral proteins.

Claims (20)

1. A method for producing a recombinant lentiviral vector particle preparation comprising the steps of:

transfecting a packaging cell line comprising a packaging construct comprising a sequence encoding a lentiviral protease containing a substitution where T is replaced with S in the DTGAD motif (SEQ ID NO: 1) and a deletion in a lentiviral packaging signal sequence with a lentiviral vector,

propagating the cell line in a suitable culture medium and

obtaining a recombinant lentiviral vector particles preparation from said culture medium.

2. The method of claim 1 , wherein said sequence encoding said protease comprises a lentiviral pol gene.

3. The method of claim 2 , further comprising a lentiviral gag gene.

4. The method of claim 1 wherein said lentiviral protease is an HIV protease.

5. The method of claim 1 wherein said lentiviral protease is a BIV protease.

6. The method of claim 1 wherein said lentiviral protease is an EIAV protease.

7. The method of claim 1 wherein said lentiviral protease is an SIV protease.

8. The method of claim 1 wherein said lentiviral protease is an FIV protease.

9. The method of claim 1 wherein expression of the lentiviral protease gene is constitutive.

10. The method of claim 1 wherein said cell line further comprises an env gene.

11. The method of claim 1 , 2 or 3 , wherein said sequence encoding a lentiviral protease is obtained from HIV genome.

12. The method of claim 1 , 2 or 3 , wherein said sequence encoding a lentiviral protease is obtained from BIV genome.

13. The method of claim 1 wherein expression of the lentiviral gag gene is constitutive.

14. The method of claim 2 or 3 wherein expression of the lentiviral pol gene is constitutive.

15. The method of claim 11 further comprising a deletion of, or mutation in, a vif gene, a vpr gene or both.

16. The method of claim 12 further comprising a deletion of, or mutation in, one or more of a vif gene, a W gene, a Y gene or a Tat gene.

17. The method of claim 1 or 10 , wherein said cell line further comprises a rev gene.

Assignments (3)
RELEASE OF SECURITY INTEREST Recorded Jan 21, 2021
From: WHITE OAK GLOBAL ADVISORS, LLC, AS ADMINISTRATIVE AGENT
To: WELLSTAT OPHTHALMICS CORPORATION
Reel/Frame 054983/0577 →
SECURITY AGREEMENT Recorded Sep 17, 2013
From: WELLSTAT OPHTHALMICS CORPORATION
To: PDL BIOPHARMA, INC.
Reel/Frame 031227/0182 →
SECURITY AGREEMENT Recorded Aug 15, 2013
From: WELLSTAT OPHTHALMICS CORPORATION
To: WHITE OAK GLOBAL ADVISORS, LLC, AS ADMINISTRATIVE AGENT
Reel/Frame 031030/0720 →
Continuity (3)
Continuation 1009700200 · Mar 13, 2002
Provisional Application 6027527500 · Mar 13, 2001
Related Publication 20070010017A1 · Jan 11, 2007